DNA methylation alterations in prostate cancer patient derived xenograft models revealed by whole genome bisulfite sequencing
DNA methylation alterations are a universal feature of cancer. In prostate cancer, site specific DNA methylation changes have been suggested as driver in disease initial and progression. Here we provide a comprehensive assessment of DNA methylation changes in prostate cancer patient derived xenograft (PDX) models. We delineate patterns of both site specific and global methylation changes and nominate novel candidates for biomarker development. Overall design: Whole genome bisulfite sequencing of PDX samples